BACKGROUND: Mutations in the BRCA1 (MIM 113705) gene are found in many families with multiple cases of breast and ovarian cancer, and women with a BRCA1 mutation are at significantly higher risk of developing breast and ovarian cancer than are the general public. METHODS: We obtained blood samples and pedigree information from 3568 unselected cases of early-onset breast cancer and 609 unselected patients with ovarian cancer from hospitals throughout Poland. Genetic testing was performed for three founder BRCA1 mutations. We also calculated the risk of breast and ovarian cancer to age 75 in the first degree relatives of carriers using Kaplan-Meier methods. RESULTS: The three founder BRCA1 mutations were identified in 273 samples (187 with 5382insC, 22 with 4153delA, and 64 with C61G). A mutation was present in 4.3% of patients with breast cancer and 12.3% of patients with ovarian cancer. The overall risk of breast cancer to age 75 in relatives was 33% and the risk of ovarian cancer was 15%. The risk for breast cancer was 42% higher among first degree relatives of carriers of the C61G missense mutation compared to other mutations (HR = 1.42; p = 0.10) and the risk for ovarian cancer was lower than average (OR = 0.26; p = 0.03). Relatives of women diagnosed with breast cancer had a higher risk of breast cancer than relatives of women diagnosed with ovarian cancer (OR = 1.7; p = 0.03). CONCLUSIONS: The risk of breast cancer in female relatives of women with a BRCA1 mutation depends on whether the proband was diagnosed with breast or ovarian cancer.
BACKGROUND: Mutations in the BRCA1 (MIM 113705) gene are found in many families with multiple cases of breast and ovarian cancer, and women with a BRCA1 mutation are at significantly higher risk of developing breast and ovarian cancer than are the general public. METHODS: We obtained blood samples and pedigree information from 3568 unselected cases of early-onset breast cancer and 609 unselected patients with ovarian cancer from hospitals throughout Poland. Genetic testing was performed for three founder BRCA1 mutations. We also calculated the risk of breast and ovarian cancer to age 75 in the first degree relatives of carriers using Kaplan-Meier methods. RESULTS: The three founder BRCA1 mutations were identified in 273 samples (187 with 5382insC, 22 with 4153delA, and 64 with C61G). A mutation was present in 4.3% of patients with breast cancer and 12.3% of patients with ovarian cancer. The overall risk of breast cancer to age 75 in relatives was 33% and the risk of ovarian cancer was 15%. The risk for breast cancer was 42% higher among first degree relatives of carriers of the C61G missense mutation compared to other mutations (HR = 1.42; p = 0.10) and the risk for ovarian cancer was lower than average (OR = 0.26; p = 0.03). Relatives of women diagnosed with breast cancer had a higher risk of breast cancer than relatives of women diagnosed with ovarian cancer (OR = 1.7; p = 0.03). CONCLUSIONS: The risk of breast cancer in female relatives of women with a BRCA1 mutation depends on whether the proband was diagnosed with breast or ovarian cancer.
Authors: A Antoniou; P D P Pharoah; S Narod; H A Risch; J E Eyfjord; J L Hopper; N Loman; H Olsson; O Johannsson; A Borg; B Pasini; P Radice; S Manoukian; D M Eccles; N Tang; E Olah; H Anton-Culver; E Warner; J Lubinski; J Gronwald; B Gorski; H Tulinius; S Thorlacius; H Eerola; H Nevanlinna; K Syrjäkoski; O-P Kallioniemi; D Thompson; C Evans; J Peto; F Lalloo; D G Evans; D F Easton Journal: Am J Hum Genet Date: 2003-04-03 Impact factor: 11.025
Authors: S A Narod; H Risch; R Moslehi; A Dørum; S Neuhausen; H Olsson; D Provencher; P Radice; G Evans; S Bishop; J S Brunet; B A Ponder Journal: N Engl J Med Date: 1998-08-13 Impact factor: 91.245
Authors: Janusz Menkiszak; Jacek Gronwald; Bohdan Górski; Anna Jakubowska; Tomasz Huzarski; Tomasz Byrski; Małgorzata Foszczyńska-Kłoda; Olga Haus; Hanna Janiszewska; Magdalena Perkowska; Izabela Brozek; Ewa Grzybowska; Helena Zientek; Stanisław Góźdź; Beata Kozak-Klonowska; Krzysztof Urbański; Roman Miturski; Jerzy Kowalczyk; Anna Pluzańska; Stanisław Niepsuj; Jan Koc; Marek Szwiec; Kazimierz Drosik; Andrzej Mackiewicz; Katarzyna Lamperska; Elwira Strózyk; Dariusz Godlewski; Małgorzata Stawicka; Bernard Waśko; Marek Bebenek; Andrzej Rozmiarek; Izabella Rzepka-Górska; Steven A Narod; Jan Lubiński Journal: Int J Cancer Date: 2003-10-10 Impact factor: 7.396
Authors: Bohdan Górski; Anna Jakubowska; Tomasz Huzarski; Tomasz Byrski; Jacek Gronwald; Ewa Grzybowska; Andrzej Mackiewicz; Malgorzata Stawicka; Marek Bebenek; Dagmara Sorokin; Łucja Fiszer-Maliszewska; Olga Haus; Hanna Janiszewska; Stanisław Niepsuj; Stanisław Góźdź; Lech Zaremba; Michał Posmyk; Maria Płuzańska; Ewa Kilar; Dorota Czudowska; Bernard Waśko; Roman Miturski; Jerzy R Kowalczyk; Krzysztof Urbański; Marek Szwiec; Jan Koc; Bogusław Debniak; Andrzej Rozmiarek; Tadeusz Debniak; Cezary Cybulski; Elzbieta Kowalska; Aleksandra Tołoczko-Grabarek; Stanisław Zajaczek; Janusz Menkiszak; Krzysztof Medrek; Bartłomiej Masojć; Marek Mierzejewski; Steven Alexander Narod; Jan Lubiński Journal: Int J Cancer Date: 2004-07-10 Impact factor: 7.396
Authors: Jan Lubinski; Catherine M Phelan; Parviz Ghadirian; Henry T Lynch; Judy Garber; Barbara Weber; Nadine Tung; Douglas Horsman; Claudine Isaacs; Alvaro N A Monteiro; Ping Sun; Steven A Narod Journal: Fam Cancer Date: 2004 Impact factor: 2.375
Authors: S A Gayther; W Warren; S Mazoyer; P A Russell; P A Harrington; M Chiano; S Seal; R Hamoudi; E J van Rensburg; A M Dunning; R Love; G Evans; D Easton; D Clayton; M R Stratton; B A Ponder Journal: Nat Genet Date: 1995-12 Impact factor: 38.330
Authors: Janet R Vos; Li Hsu; Richard M Brohet; Marian J E Mourits; Jakob de Vries; Kathleen E Malone; Jan C Oosterwijk; Geertruida H de Bock Journal: J Clin Oncol Date: 2015-07-06 Impact factor: 44.544
Authors: Funda Meric-Bernstam; Angelica M Gutierrez-Barrera; Jennifer Litton; Lauren Mellor-Crummey; Kaylene Ready; Ana Maria Gonzalez-Angulo; Karen H Lu; Gabriel N Hortobagyi; Banu K Arun Journal: Breast J Date: 2012-12-10 Impact factor: 2.431
Authors: Jacek Gronwald; Tomasz Byrski; Tomasz Huzarski; Oleg Oszurek; Anna Janicka; Jolanta Szymanska-Pasternak; Bohdan Górski; Janusz Menkiszak; Izabella Rzepka-Górska; Jan Lubinski Journal: Hered Cancer Clin Pract Date: 2008-06-15 Impact factor: 2.857
Authors: C Cybulski; D Wokołorczyk; W Kluźniak; A Jakubowska; B Górski; J Gronwald; T Huzarski; A Kashyap; T Byrski; T Dębniak; A Gołąb; B Gliniewicz; A Sikorski; J Switała; T Borkowski; A Borkowski; A Antczak; L Wojnar; J Przybyła; M Sosnowski; B Małkiewicz; R Zdrojowy; P Sikorska-Radek; J Matych; J Wilkosz; W Różański; J Kiś; K Bar; P Bryniarski; A Paradysz; K Jersak; J Niemirowicz; P Słupski; P Jarzemski; M Skrzypczyk; J Dobruch; P Domagała; S A Narod; J Lubiński Journal: Br J Cancer Date: 2012-11-13 Impact factor: 7.640
Authors: Elżbieta Złowocka-Perłowska; Aleksandra Tołoczko-Grabarek; Steven A Narod; Jan Lubiński Journal: Hered Cancer Clin Pract Date: 2022-04-08 Impact factor: 2.857
Authors: J Gronwald; C Cybulski; W Piesiak; J Suchy; T Huzarski; T Byrski; B Gorski; T Debniak; M Szwiec; D Wokolowczyk; M Matuszewski; P Sun; J Lubinski; S A Narod Journal: Br J Cancer Date: 2009-05-05 Impact factor: 7.640